The RPM Report focuses on a new effort to revise and improve the way the FDA approves proposed proprietary drug names. The agency kicks back about 40 percent of the brand names suggested by sponsors, creating a great deal of frustration with the process. The industry wants more predictability and more insight into what it needs to do to get an approval. But a new pilot program aimed at improving the process is instead raising fears that the name-game will only grow more complex.
- read the story [1] from RPM Report
Related Articles:
Drug name psychology, or the power of Z [2]
Drug marketing costs double R&D [3]
IMS lists best drug launches of all time [4]
Links:
[1] http://therpmreport.com/Free/aced1614-935c-4fa7-b739-746e5eab3bd3.aspx?utm_source=smartbrief
[2] http://www.fiercepharma.com/story/drug-name-psychology-or-power-z/2008-01-18
[3] http://www.fiercepharma.com/story/drug-marketing-costs-double-r-d/2008-01-04
[4] http://www.fiercepharma.com/story/ims-lists-best-drug-launches-all-time/2007-08-22